Biotech Daily

Daily news on ASX-listed biotechnology companies

Dr Boreham's Crucible

Tim Boreham contributes weekly analyses of the sector.

Tim is an experienced business writer having written for three decades at major business publications, specializing in banking, accounting, resources, technology, telecoms, agriculture, property trusts and - of course - the life sciences.

Tim was best known as the writer of the Criterion investment column analyzing ASX-listed companies in a style accessible to retail investors. A quirk of the column was that it offered 'buy' and 'sell' recommendations in a journalist context.

Tim is proud to have no financial qualifications other than an outdated Certificate in Financial Markets and a dedicated following from investors, brokers and analysts and says he is yet to be charged by ASIC despite penning Criterion for more than 10 years.

Tim holds a Bachelor of Arts in Journalism from the Royal Melbourne Institute of Technology.

2024

Emvision Medical Devices (Oct 4, 2024)

Cynata Therapeutics (Sep 27, 2024)

Impedimed (Sep 20, 2024)

Medical Developments (Sep 13, 2024)

LBT Innovations (Sep 6, 2024)

Telix Pharmaceuticals (Aug 30, 2024)

Pro Medicus (Aug 23, 2024)

Alcidion (Aug 16, 2024)

Arovella Therapeutics (Aug 9, 2024)

Actinogen Medical (Aug 2, 2024)

Aroa Biosurgery (Jul 26, 2024)

Compumedics (Jul 19, 2024)

SDI (Jul 12, 2024)

Starpharma Holdings (Jul 5, 2024)

Radiopharm Theranostics (Jun 28, 2024)

Neurotech International (Jun 21, 2024)

Island Pharmaceuticals (Jun 14, 2024)

Genetic Signatures (Jun 7, 2024)

Amplia Therapeutics (May 31, 2024)

Proteomics International Labs (May 24, 2024)

Blinklab (May 17, 2024)

Immuron (May 10, 2024)

Invion (May 3, 2024)

Opthea (Apr 26, 2024)

4D Medical (Apr 19, 2024)

Bcal Diagnostics (Apr 12, 2024)

Race Oncology (Apr 5, 2024)

Universal Biosensors (Mar 28, 2024)

Hydrix (Mar 22, 2024)

Vitura Health (Mar 15, 2024)

Neuren Pharmaceuticals (Mar 8, 2024)

Clinuvel Pharmaceuticals (Feb 29, 2024)

Cochlear (Feb 23, 2024)

CSL (Feb 16, 2024)

Artrya (Feb 9, 2024)

Resmed (Feb 2, 2024)

 

2023

End Of Year Report Card (Dec 15, 2023)

Botanix Pharmaceuticals (Dec 8, 2023)

Imugene (Nov 30, 2023)

Optiscan Imaging Ltd (Nov 24, 2023)

PYC Therapeutics (Nov 17, 2023)

Nanosonics (Nov 10, 2023)

Paradigm Biopharmaceuticals (Nov 3, 2023)

Pharmaxis (Oct 27, 2023)

Pro Medicus (Oct 20, 2023)

Dimerix (Oct 13, 2023)

Cyclopharm (Oct 6, 2023)

Next Science (Sep 29, 2023)

Argenica Therapeutics (Sep 22, 2023)

Clarity Pharmaceuticals (Sep 15, 2023)

Painchek (Sep 8, 2023)

Curvebeam AI (Aug 31, 2023)

Cleo Diagnostics (Aug 25, 2023)

Micro-X (Aug 18, 2023)

IDT Australia (Aug 11, 2023)

Mesoblast (Aug 4, 2023)

Telix Pharmaceuticals (Jul 28, 2023)

Cynata Therapeutics (Jul 21, 2023)

Arovella Therapeutics (Jul 14, 2023)

Microba Life Sciences (Jul 7, 2023)

Polynovo (Jun 30, 2023)

Tissue Repair (Jun 23, 2023)

Lumos Diagnostics (Jun 16, 2023)

Nova Eye Medical (Jun 9, 2023)

Dimerix (Jun 2, 2023)

EBR Systems Inc (May 26, 2023)

Chimeric Therapeutics (May 19, 2023)

Cyclopharm (May 12, 2023)

Impedimed (May 5, 2023)

Control Bionics (Apr 28, 2023)

Volpara Health Technologies (Apr 21, 2023)

Medadvisor (Apr 14, 2023)

Radiopharm Theranostics (Apr 6, 2023)

Memphasys (Mar 31, 2023)

Avita Medical (Mar 24, 2023)

Neuren Pharmaceuticals (Mar 17, 2023)

SDI (Mar 10, 2023)

Bluechiip (Mar 3, 2023)

Cochlear (Feb 24, 2023)

CSL (Feb 17, 2023)

Imagion Biosystems (Feb 10, 2023)

Resmed (Feb 3, 2023)

 

2022

 

 

2021

 
 

 

2020

 
 

 

2019

 
 

 

2018

 
 

 

2017

 

* Disclosure:
Dr
Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. Nor is he a licenced financial adviser.

Subscribe to Biotech Daily

TOP